跳至主要内容
临床试验/ISRCTN62728743
ISRCTN62728743已完成不适用

Targeted pharmacological reversal of electrical remodeling after cardioversio

German Atrial Fibrillation competence NETwork (AFNET) (Kompetenznetz Vorhofflimmern) (Germany)0 个研究点目标入组 635 人开始时间: 2005年8月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
635

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Documented persistent atrial fibrillation
  • 2. Age of 18 years
  • 3. Documented oral anticoagulation (international normalized ratio [INR] =2) for at least three weeks prior to inclusion, or exclusion of left atrial thrombi by trans-esophageal echocardiography
  • 4. Written informed consent of the patient

排除标准

  • Exclusion criteria are based on the approval information of flecainide and include, among others, patients with known coronary artery disease or typical angina pectoris, patients with depressed left ventricular ejection fraction (<40%), patients with severely depressed renal or hepatic function, patients with overt thyroid disease, and patients with known Brugada syndrome, sinus node dysfunction or higher degree AV nodal block.

研究者

发起方
German Atrial Fibrillation competence NETwork (AFNET) (Kompetenznetz Vorhofflimmern) (Germany)

相似试验